Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03383588 · ClinicalTrials.gov registry record · Phase 2
Subcutaneous Bupivacaine Decrease Post-op Pain in Patients Undergoing C-Section
A Phase 2 study, sponsored by Montefiore Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT03383588: Clinical Trial Phase 2 study, sponsored by Montefiore Medical Center.
NCT03383588 is a Phase 2 study that was terminated before completion, run by Montefiore Medical Center. The registered enrollment target is 26 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03383588, a Phase 2 study, was terminated before completion, sponsored by Montefiore Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if giving an injection of numbing medication at the incision at the end of cesarean will help control pain AFTER cesarean delivery. This study seeks to assess pain relief with incisional infiltration of local anesthetic during cesareans performed under spinal anesthesia also using intrathecal opioids. Participants will receive the usual regimen of pain medication in spinal anesthesia. At the end of the cesarean delivery, while the participants are still under the spinal medication, participants will receive an injection, at the incision, either numbing medication (with or without epinephrine) or sterile saline. After the cesarean delivery, participants will receive, by mouth, commonly prescribed pain medications - these medications are oxycodone (an opioid/ narcotic), acetaminophen (or more commonly known as Tylenol), and ibuprofen.
Primary Outcome
Cumulative opioid pain medication used in the first 24 hours postoperatively as recorded in the medical record
Interventions
- DRUG Bupivacaine
- DRUG Epinephrine
- DRUG Morphine
- DRUG Fentanyl
- OTHER Saline solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2018-07-19 |
| Est. Completion | 2018-12-31 |
| Phase | Phase 2 |
Why NCT03383588 stopped before completion
NCT03383588 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 5 interventions - of which Bupivacaine is the first listed.
NCT03383588 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03383588 about?
NCT03383588 is a clinical study titled "Subcutaneous Bupivacaine Decrease Post-op Pain in Patients Undergoing C-Section". The purpose of this study is to determine if giving an injection of numbing medication at the incision at the end of cesarean will help control pain AFTER cesarean delivery. This study seeks to assess pain relief with incisional infiltration of local anesthetic during cesareans performed under spina...
What is the current status of trial NCT03383588?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2018-07-19. Estimated completion is 2018-12-31.
What interventions are being tested in trial NCT03383588?
The interventions under investigation include: Bupivacaine (DRUG), Epinephrine (DRUG), Morphine (DRUG), Fentanyl (DRUG), Saline solution (OTHER).
Who is sponsoring clinical trial NCT03383588?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03383588's enrollment target sits among peer trials
26 1708th of 2000 higher than 282 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI